查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447054

至 2030 年女性保健市场预测 - 按药物（Actonel、Forteo、Mirena、Nuvaring、Ortho Tri-Cy Lo (28)、Premarin、Prolia、Reclast/Aclasta 和其他药物）、配销通路、应用和地理位置进行的全球分析

Women Healthcare Market Forecasts to 2030 - Global Analysis By Drug (Actonel, Forteo, Mirena, Nuvaring, Ortho Tri-Cy Lo (28), Premarin, Prolia, Reclast/Aclasta and Other Drugs), Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球女性医疗保健市场规模为 175 亿美元，预计到 2030 年将达到 501 亿美元，预测期内复合CAGR为 16.2%。它指的是专门针对解决各年龄层女性独特的医疗保健需求和担忧的医疗保健服务、产品和技术领域。这涵盖了广泛的医疗领域，包括生殖健康、孕产妇护理、妇科问题、乳房健康、更年期管理和各种特定性别的病症。此外，它还包括乳癌、子宫颈癌、骨质疏鬆症和其他主要影响女性的疾病等疾病的诊断工具、筛检测试和治疗。

根据美国国家骨质疏鬆基金会的数据，在全球范围内，骨质疏鬆症影响着超过800 万名50 岁以上的女性。根据世界卫生组织的数据，2016 年，在亚洲、非洲和南美洲等发展中国家，骨质疏鬆症患者人数约2,100 万人。15-19 岁少女怀孕。

市场动态：

司机：

女性人口增加

由于女性占全球人口的很大一部分，她们的医疗保健需求多种多样且复杂，跨越从青春期到更年期及以后的各个生命阶段。这种人口趋势促使人们更加关注和投资针对女性医疗保健服务和产品，以满足其独特的生理和医疗需求。此外，人们对预防保健的认识不断提高、医疗技术的进步以及旨在促进妇女健康的倡议都进一步推动了市场的扩张。

克制：

财务限制

许多女性面临经济挑战，限制了她们承担医疗保健的能力，包括常规检查、筛检、药物和专门治疗。如果没有足够的经济资源，女性可能会推迟寻求医疗服务或完全放弃寻求医疗服务，从而导致健康状况恶化和医疗保健差距扩大。然而，健康保险的费用和自付费用可能令人望而却步，特别是对于低收入个人和没有全面保险的人来说。

机会：

妇女赋权与宣传

随着人们对性别平等的认识和重视不断增强，女性开始掌控自己的健康，并要求更好地获得针对其特定需求的医疗保健服务。这种赋权导致了针对女性健康问题的研究和开发激增，从而产生了创新的治疗、诊断和预防措施。此外，宣传工作影响了政策制定者优先考虑妇女的医疗保健，从而改善了医疗保健基础设施和支持妇女生殖权利、孕产妇健康和避孕的政策。

威胁：

生殖权利和计划生育的机会

法律和监管障碍以及社会耻辱可能会限制获得全面的生殖保健服务，例如避孕、堕胎和产前护理。生殖权利的限制不仅妨碍妇女对其生殖健康做出知情选择的能力，而且还会导致负面健康后果，包括不安全堕胎和孕产妇死亡。此外，获得计划生育服务的不平等对边缘化社区产生了不成比例的影响，加剧了现有的不平等。

Covid-19 影响：

虽然世界各地的医疗保健系统专注于控制病毒，但常规的妇女健康服务却面临中断，包括预防性筛检、产前护理和避孕药具的取得。封锁措施和不堪重负的医疗设施导致预约延迟和服务利用率下降，加剧了现有的健康差距。然而，经济衰退对女性的影响尤其严重，导致其负担能力和获得医疗服务的机会减少。向远距医疗的转变提供了一定的护理连续性，但也凸显了数位存取和技术素养的差异，进一步影响了边缘化人群。

Actonel 细分市场预计将在预测期内成为最大的细分市场

由于它用于预防和治疗骨质疏鬆症（一种以骨密度降低和骨折易感性增加为特征的疾病），Actonel 细分市场在预计期间占据了女性医疗保健市场的主导份额。透过为骨质疏鬆症管理提供有效的治疗选择，Actonel 有助于促进女性骨骼健康并降低骨折风险，从而提高她们的整体福祉和生活品质。该部门的存在不仅满足了女性的医疗需求，还有助于提高人们对骨质疏鬆症和骨骼健康重要性的认识，从而使女性能够为自己的健康采取积极措施。

预计子宫内膜异位症领域在预测期内复合CAGR最高

预计子宫内膜异位症领域在预测期内将出现利润丰厚的成长。子宫内膜异位症是一种类似子宫内膜的组织在子宫外生长的疾病，影响全球数百万名女性，导致慢性疼痛和生育问题。对子宫内膜异位症的认识和理解的提高导致了对开发先进诊断工具的投资增加，例如成像技术和生物标记测定，从而实现早期检测和个性化治疗策略。此外，製药公司也积极开发子宫内膜异位症潜在机制的新药，为患者提供更有效的症状管理，并有可能改善他们的生活品质。

占比最大的地区：

由于人们对预防保健和健康意识的增强和重视，导致对女性健康服务和产品的需求增加，北美地区在预测期内占据了最大的市场份额。医疗技术的进步，特别是在妇科、产科和生殖健康等领域的进步，扩大了治疗选择并改善了结果，进一步推动了市场的区域成长。此外，政府的支持性倡议，加上强大的医疗基础设施和保险覆盖范围，使该地区的女性更容易获得医疗保健。

复合CAGR最高的地区：

由于个人化医疗利用基因检测、生物标记分析和资料分析等先进技术，根据患者独特的基因组成、生活方式和环境因素量身定制医疗保健策略，亚太地区预计将在预期期间大幅增长。在女性医疗保健领域，这种方法可以对乳癌、生殖健康障碍和荷尔蒙失衡等疾病进行更准确的诊断和针对性治疗。此外，透过优化治疗效果和最大限度地减少不良反应，个人化医疗不仅可以改善患者的治疗效果，还可以提高整体医疗质量，使其成为推动市场成长的关键力量。

主要进展：

2024 年 2 月，诺华以 29 亿美元收购以癌症为中心的 MorphoSys。诺华将向股东提供每股 68.00 欧元的现金，并在交易完成后将 MorphoSys 私有化，这取决于某些条件，包括 MorphoSys 股本 65% 的最低接受门槛和监管许可。

2022年9月，奥拉帕尼在中国获得批准，成为贝伐珠单抗一线维持治疗同源重组缺陷（HRD）阳性晚期卵巢癌的药物。

2022 年 1 月，Jackson Memorial 妇女医院、AdventHealth Celebration 和 HCA Florida Healthcare 医疗中心使用 Memic Innovative Practice 的机器人手术技术 Homins 手术系统进行妇科手术。

我们的报告提供了什么：

  • 区域和国家层面的市场份额评估
  • 对新进入者的策略建议
  • 涵盖2021年、2022年、2023年、2026年及2030年的市场资料
  • 市场趋势（驱动因素、限制因素、机会、威胁、挑战、投资机会和建议）
  • 根据市场预测提出关键业务部门的策略建议
  • 竞争性景观美化绘製主要共同趋势
  • 公司概况，包括详细的策略、财务状况和最新发展
  • 反映最新技术进步的供应链趋势

免费客製化产品：

本报告的所有客户都将有权获得以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 个）
    • 关键参与者的 SWOT 分析（最多 3 个）
  • 区域细分
    • 根据客户的兴趣对任何主要国家的市场估计、预测和CAGR（註：取决于可行性检查）
  • 竞争基准化分析
    • 根据产品组合、地理分布和策略联盟对主要参与者基准化分析

目录

第 1 章：执行摘要

第 2 章：前言

  • 抽象的
  • 股东
  • 研究范围
  • 研究方法论
    • 资料探勘
    • 数据分析
    • 数据验证
    • 研究方法
  • 研究来源
    • 主要研究来源
    • 二手研究来源
    • 假设

第 3 章：市场趋势分析

  • 介绍
  • 司机
  • 限制
  • 机会
  • 威胁
  • 应用分析
  • 新兴市场
  • Covid-19 的影响

第 4 章：波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争竞争

第 5 章：全球女性保健市场：按药物分类

  • 介绍
  • 阿克托内尔
  • 福尔泰奥
  • 曼月乐
  • 努瓦林
  • 邻三环洛 (28)
  • 倍美力
  • 普罗利亚
  • 重熔/密固达
  • 其他药物

第 6 章：全球女性保健市场：按配销通路

  • 介绍
  • 零售药局
  • 线上提供者
  • 医院药房

第 7 章：全球女性保健市场：按应用分类

  • 介绍
  • 停经
  • 荷尔蒙不孕症
  • 停经后骨质疏鬆症
  • 子宫内膜异位症
  • 避孕药具
  • 其他应用

第 8 章：全球女性保健市场：依地理位置

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太地区其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿联酋
    • 卡达
    • 南非
    • 中东和非洲其他地区

第 9 章：主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 扩充
  • 其他关键策略

第 10 章：公司概况

  • Agile Therapeutics Inc
  • Allergan
  • Apothecus Pharmaceutical
  • Bayer AG
  • Blairex Laboratories
  • Ferring Pharmaceuticals
  • Lupin Limited
  • Mylan NV
  • Novartis AG
  • Pfizer Inc
Product Code: SMRC25315

According to Stratistics MRC, the Global Women Healthcare Market is accounted for $17.5 billion in 2023 and is expected to reach $50.1 billion by 2030 growing at a CAGR of 16.2% during the forecast period. It refers to the sector of healthcare services, products, and technologies specifically targeted towards addressing the unique healthcare needs and concerns of women across all age groups. This encompasses a wide range of medical areas, including reproductive health, maternal care, gynecological issues, breast health, menopause management, and various gender-specific conditions. Additionally, it encompasses diagnostic tools, screening tests, and treatments for conditions such as breast cancer, cervical cancer, osteoporosis, and other diseases that predominantly affect women.

According to the National Osteoporosis Foundation, across the globe, osteoporosis affects more than 8 million women over the age of 50. According to the WHO, in 2016, in developing countries such as Asia, Africa, and South America, there were around 21 million pregnancies among adolescent girls aged 15-19 years.

Market Dynamics:

Driver:

Increasing female population

As women constitute a substantial portion of the global population, their healthcare needs are diverse and complex, spanning across various life stages from adolescence to menopause and beyond. This demographic trend is prompting greater attention and investment in women's healthcare services and products tailored to address their unique physiological and medical requirements. Moreover, rising awareness about preventive care, advancements in medical technology, and initiatives aimed at promoting women's health are further fueling market expansion.

Restraint:

Financial constraints

Many women face economic challenges that limit their ability to afford healthcare, including routine check-ups, screenings, medications, and specialized treatments. Without adequate financial resources, women may delay seeking care or forego it altogether, leading to worsened health outcomes and increased healthcare disparities. However, the cost of health insurance and out-of-pocket expenses can be prohibitive, particularly for low-income individuals and those without comprehensive coverage.

Opportunity:

Women's empowerment and advocacy

With increasing awareness and emphasis on gender equality, women are taking charge of their health and demanding better access to healthcare services tailored to their specific needs. This empowerment has led to a surge in research and development focused on women's health issues, resulting in innovative treatments, diagnostics, and preventive measures. Furthermore, advocacy efforts have influenced policymakers to prioritize women's healthcare, leading to improved healthcare infrastructure and policies supporting women's reproductive rights, maternal health, and access to contraception.

Threat:

Reproductive rights and access to family planning

Legal and regulatory barriers, along with societal stigmas, can limit access to comprehensive reproductive healthcare services such as contraception, abortion, and prenatal care. Restrictions on reproductive rights not only impede women's ability to make informed choices about their reproductive health but also contribute to negative health outcomes, including unsafe abortions and maternal mortality. Additionally, disparities in access to family planning services disproportionately affect marginalized communities, exacerbating existing inequalities.

Covid-19 Impact:

While healthcare systems worldwide focused on managing the virus, routine women's health services faced disruptions, including preventive screenings, prenatal care, and access to contraceptives. Lockdown measures and overwhelmed healthcare facilities led to postponed appointments and decreased utilization of services, exacerbating existing health disparities. However, economic downturns disproportionately affected women, leading to reduced affordability and access to healthcare services. The shift towards telemedicine offered some continuity in care but also highlighted disparities in digital access and technology literacy, further impacting marginalized populations.

The actonel segment is expected to be the largest during the forecast period

As it is utilized for the prevention and treatment of osteoporosis, a condition characterized by reduced bone density and increased susceptibility to fractures, Actonel segment commanded the dominant share in the Women Healthcare market over the projected period. By offering an effective therapeutic option for osteoporosis management, Actonel helps to promote bone health and reduce the risk of fractures in women, thereby enhancing their overall well-being and quality of life. This segment's presence not only meets the medical needs of women but also contributes to raising awareness about osteoporosis and the importance of bone health, thus empowering women to take proactive measures for their health.

The endometriosis segment is expected to have the highest CAGR during the forecast period

Endometriosis segment is estimated to witness lucrative growth during the forecast period. Endometriosis, a disorder where tissue similar to the lining of the uterus grows outside the womb, affects millions of women globally, causing chronic pain and fertility issues. The heightened awareness and understanding of endometriosis have led to increased investments in developing advanced diagnostic tools, such as imaging techniques and biomarker assays, enabling early detection and personalized treatment strategies. Additionally, pharmaceutical companies are actively engaged in the development of novel drugs targeting the underlying mechanisms of endometriosis, offering patients more effective symptom management and potentially improving their quality of life.

Region with largest share:

Owing to the increased awareness and emphasis on preventive care and wellness have led to higher demand for women's health services and products, North America region commanded the largest share of the market over the prognosis period. Advancements in medical technology, particularly in areas such as gynecology, obstetrics, and reproductive health, have expanded treatment options and improved outcomes, further driving regional growth in the market. Moreover, supportive government initiatives, coupled with robust healthcare infrastructure and insurance coverage, have made healthcare more accessible to women across the region.

Region with highest CAGR:

Asia Pacific region is estimated to witness substantial growth during the anticipated period as personalized medicine utilizes advanced technologies such as genetic testing, biomarker analysis and data analytics to customize healthcare strategies based on a patient's unique genetic makeup, lifestyle, and environmental factors. In women's healthcare, this approach enables more accurate diagnoses and targeted therapies for conditions like breast cancer, reproductive health disorders and hormonal imbalances. Furthermore, by optimizing treatment efficacy and minimizing adverse effects, personalized medicine not only improves patient outcomes but also enhances overall healthcare quality, making it a pivotal force driving growth in the market.

Key players in the market

Some of the key players in Women Healthcare market include Agile Therapeutics Inc, Allergan, Apothecus Pharmaceutical, Bayer AG, Blairex Laboratories, Ferring Pharmaceuticals, Lupin Limited, Mylan NV, Novartis AG and Pfizer Inc.

Key Developments:

In February 2024, Novartis to acquire cancer-centric MorphoSys for $2.9 bln. Novartis will offer shareholders 68.00 euros per share in cash and take MorphoSys private after the deal, which is contingent on certain conditions, including a minimum acceptance threshold of 65% of MorphoSys' share capital and regulatory clearances.

In September 2022, Lynparza was given clearance in China as the first line of maintenance therapy with bevacizumab for advanced ovarian cancer with homologous recombination deficit (HRD) positivity.

In January 2022, The women's hospital at Jackson Memorial, AdventHealth Celebration, and HCA Florida Healthcare's Medical Center using the Robotic surgical technology, Homins surgical system by Memic Innovative Surgery for gynecological procedures.

Drugs Covered:

  • Actonel
  • Forteo
  • Mirena
  • Nuvaring
  • Ortho Tri-Cy Lo (28)
  • Premarin
  • Prolia
  • Reclast/Aclasta
  • Other Drugs

Distribution Channels Covered:

  • Retail Pharmacies
  • Online Providers
  • Hospital Pharmacies

Applications Covered:

  • Menopause
  • Hormonal Infertility
  • Postmenopausal Osteoporosis
  • Endometriosis
  • Contraceptives
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Women Healthcare Market, By Drug

  • 5.1 Introduction
  • 5.2 Actonel
  • 5.3 Forteo
  • 5.4 Mirena
  • 5.5 Nuvaring
  • 5.6 Ortho Tri-Cy Lo (28)
  • 5.7 Premarin
  • 5.8 Prolia
  • 5.9 Reclast/Aclasta
  • 5.10 Other Drugs

6 Global Women Healthcare Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Retail Pharmacies
  • 6.3 Online Providers
  • 6.4 Hospital Pharmacies

7 Global Women Healthcare Market, By Application

  • 7.1 Introduction
  • 7.2 Menopause
  • 7.3 Hormonal Infertility
  • 7.4 Postmenopausal Osteoporosis
  • 7.5 Endometriosis
  • 7.6 Contraceptives
  • 7.7 Other Applications

8 Global Women Healthcare Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Agile Therapeutics Inc
  • 10.2 Allergan
  • 10.3 Apothecus Pharmaceutical
  • 10.4 Bayer AG
  • 10.5 Blairex Laboratories
  • 10.6 Ferring Pharmaceuticals
  • 10.7 Lupin Limited
  • 10.8 Mylan NV
  • 10.9 Novartis AG
  • 10.10 Pfizer Inc

List of Tables

  • Table 1 Global Women Healthcare Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
  • Table 3 Global Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
  • Table 4 Global Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
  • Table 5 Global Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
  • Table 6 Global Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
  • Table 7 Global Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
  • Table 8 Global Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
  • Table 9 Global Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
  • Table 10 Global Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
  • Table 11 Global Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 12 Global Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 13 Global Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 14 Global Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 15 Global Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 16 Global Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
  • Table 18 Global Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
  • Table 19 Global Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
  • Table 20 Global Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
  • Table 21 Global Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
  • Table 22 Global Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 23 North America Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
  • Table 24 North America Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
  • Table 25 North America Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
  • Table 26 North America Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
  • Table 27 North America Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
  • Table 28 North America Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
  • Table 29 North America Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
  • Table 30 North America Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
  • Table 31 North America Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
  • Table 32 North America Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
  • Table 33 North America Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 34 North America Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 35 North America Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 36 North America Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 37 North America Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 38 North America Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
  • Table 39 North America Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
  • Table 40 North America Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
  • Table 41 North America Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
  • Table 42 North America Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
  • Table 43 North America Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
  • Table 44 North America Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 45 Europe Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
  • Table 46 Europe Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
  • Table 47 Europe Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
  • Table 48 Europe Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
  • Table 49 Europe Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
  • Table 50 Europe Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
  • Table 51 Europe Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
  • Table 52 Europe Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
  • Table 53 Europe Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
  • Table 54 Europe Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
  • Table 55 Europe Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 56 Europe Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 57 Europe Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 58 Europe Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 59 Europe Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 60 Europe Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
  • Table 61 Europe Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
  • Table 62 Europe Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
  • Table 63 Europe Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
  • Table 64 Europe Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
  • Table 65 Europe Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
  • Table 66 Europe Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 67 Asia Pacific Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
  • Table 68 Asia Pacific Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
  • Table 69 Asia Pacific Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
  • Table 70 Asia Pacific Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
  • Table 71 Asia Pacific Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
  • Table 72 Asia Pacific Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
  • Table 73 Asia Pacific Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
  • Table 74 Asia Pacific Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
  • Table 75 Asia Pacific Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
  • Table 76 Asia Pacific Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
  • Table 77 Asia Pacific Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 78 Asia Pacific Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 79 Asia Pacific Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 80 Asia Pacific Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 81 Asia Pacific Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 82 Asia Pacific Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
  • Table 83 Asia Pacific Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
  • Table 84 Asia Pacific Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
  • Table 85 Asia Pacific Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
  • Table 86 Asia Pacific Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
  • Table 87 Asia Pacific Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
  • Table 88 Asia Pacific Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 89 South America Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
  • Table 90 South America Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
  • Table 91 South America Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
  • Table 92 South America Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
  • Table 93 South America Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
  • Table 94 South America Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
  • Table 95 South America Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
  • Table 96 South America Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
  • Table 97 South America Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
  • Table 98 South America Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
  • Table 99 South America Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 100 South America Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 101 South America Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 102 South America Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 103 South America Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 104 South America Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
  • Table 105 South America Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
  • Table 106 South America Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
  • Table 107 South America Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
  • Table 108 South America Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
  • Table 109 South America Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
  • Table 110 South America Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 111 Middle East & Africa Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
  • Table 112 Middle East & Africa Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
  • Table 113 Middle East & Africa Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
  • Table 114 Middle East & Africa Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
  • Table 115 Middle East & Africa Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
  • Table 116 Middle East & Africa Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
  • Table 117 Middle East & Africa Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
  • Table 118 Middle East & Africa Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
  • Table 119 Middle East & Africa Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
  • Table 120 Middle East & Africa Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
  • Table 121 Middle East & Africa Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 122 Middle East & Africa Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 123 Middle East & Africa Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 124 Middle East & Africa Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 125 Middle East & Africa Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 126 Middle East & Africa Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
  • Table 127 Middle East & Africa Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
  • Table 128 Middle East & Africa Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
  • Table 129 Middle East & Africa Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
  • Table 130 Middle East & Africa Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
  • Table 131 Middle East & Africa Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
  • Table 132 Middle East & Africa Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)